Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0.22 | 0.5 |
Brugia malayi | hypothetical protein | 0.0026 | 0.22 | 0.22 |
Leishmania major | hypothetical protein, conserved | 0.0026 | 0.22 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.246 | 0.246 |
Brugia malayi | hypothetical protein | 0.0017 | 0.0373 | 0.0373 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.22 | 0.22 |
Brugia malayi | intermediate filament protein | 0.0028 | 0.2561 | 0.2561 |
Onchocerca volvulus | 0.0028 | 0.2561 | 0.5 | |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0026 | 0.22 | 0.5 |
Onchocerca volvulus | 0.0028 | 0.2561 | 0.5 | |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0026 | 0.22 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.22 | 0.5 |
Loa Loa (eye worm) | intermediate filament protein | 0.0028 | 0.2561 | 0.2561 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0026 | 0.22 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0028 | 0.2561 | 0.2561 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.22 | 0.5 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0028 | 0.2561 | 0.2561 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0.22 | 0.5 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0028 | 0.2561 | 0.2561 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | = 411 % | Activation of glucokinase-mediated of glucose phosphorylation in Sprague-Dawley rat hepatocytes assessed as release of [3H]H2O from [2-3H]glucose at 30 uM after 3 hrs | ChEMBL. | 19746978 |
Activity (binding) | = 489 nM | Activation of His-tagged human recombinant liver glucokinase expressed in Escherichia coli BL21 (DE3) assessed as drug level required for half-maximal activation | ChEMBL. | 19746978 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.